Innate Pharma IPHA
NASDAQ IPHA
$1.59 +0.05 (+3.25%)
As of: Nov 11, 2026 · 3:56 PM EST

Innate Pharma (IPHA) Research & Development (2019)

Updated

Innate Pharma's Research & Development was -$19.62 million in the quarter ended Jun 30, 2026, compared with -$23.23 million a year earlier.

Analysis

Innate Pharma (IPHA) Research & Development (2019) Analysis & Trends

On a trailing twelve-month basis, Innate Pharma's Research & Development was -$149.17 million through Jun 30, 2026; for the year ended Dec 31, 2025, it was -$49.28 million.

  • In earlier years, Research & Development was -$56.26 million in the year ended Dec 31, 2024, -$60.6 million in the year ended Dec 31, 2023, -$54.45 million in the year ended Dec 31, 2022 and -$53.77 million in the year ended Dec 31, 2021.
  • The figure for the quarter ended Jun 30, 2026 marks the highest quarterly Research & Development in data going back to the quarter ended Jun 30, 2019.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) R&D (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 4.25 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 4.65 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 2.57 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 4.54 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 3.89 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 2.11 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 1.61 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 3.02 Bn
10 Innate Pharma 142.45 Mn -64.74 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2019 41.11 Mn
API Access

Innate Pharma Research & Development API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=research-and-development&ticker=IPHA&period=max&api_key=YOUR_API_KEY